Effects of Commercially Available Soy Products on PSA in Androgen-deprivation-naïve and Castration-resistant Prostate Cancer

Monika Joshi, MD; Nicole M. Agostino, MD; Rebecca Gingrich, MSN; Joseph J. Drabick, MD, FACP


South Med J. 2011;104(11):736-740. 

In This Article


Our clinical experience in 10 men with rising PSA levels after prior RP and RT suggests that treatment with commercially available soy products can have beneficial effects on PSA levels and PSA kinetics in some men. This effect can be sustained so that it could delay the need for ADT and/or other potentially morbid interventions. We observed that soy can benefit patients with CR prostate cancer. Our study was clearly limited in its sample size and its retrospective nature. Our study, like others of this modality, begs the question of why some men respond whereas others do not and why the response can be lost over time. Further study of this modality is needed because soy is an inexpensive, readily available, and well-tolerated means to delay the progression of prostate cancer, thus delaying the need for ADT or other potentially morbid treatments.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: